


Dagrocorat

Cat. No.:	HY-16718												
CAS No.:	1044535-52-5												
Molecular Formula:	C ₂₉ H ₂₉ F ₃ N ₂ O ₂												
Molecular Weight:	494.55												
Target:	Glucocorticoid Receptor; Cytochrome P450												
Pathway:	Immunology/Inflammation; Vitamin D Related/Nuclear Receptor; Metabolic Enzyme/Protease												
Storage:	<table border="0"> <tr> <td>Powder</td> <td>-20°C</td> <td>3 years</td> </tr> <tr> <td></td> <td>4°C</td> <td>2 years</td> </tr> <tr> <td>In solvent</td> <td>-80°C</td> <td>6 months</td> </tr> <tr> <td></td> <td>-20°C</td> <td>1 month</td> </tr> </table>	Powder	-20°C	3 years		4°C	2 years	In solvent	-80°C	6 months		-20°C	1 month
Powder	-20°C	3 years											
	4°C	2 years											
In solvent	-80°C	6 months											
	-20°C	1 month											



SOLVENT & SOLUBILITY

In Vitro	DMSO : 250 mg/mL (505.51 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.0220 mL	10.1102 mL	20.2204 mL
		5 mM	0.4044 mL	2.0220 mL	4.0441 mL
		10 mM	0.2022 mL	1.0110 mL	2.0220 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 6.25 mg/mL (12.64 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 6.25 mg/mL (12.64 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	Dagrocorat (PF-00251802) is an orally active and selective high-affinity partial agonist of the glucocorticoid receptor. Dagrocorat is also a time-dependent reversible inhibitor of CYP3A (IC ₅₀ =1.3 μM in human liver microsomes) and CYP2D6 (K _i =0.57 μM in human liver microsomes). Dagrocorat can be used for the research of rheumatoid arthritis ^[1] .	
IC₅₀ & Target	CYP3A	CYP2D6
In Vitro	Dagrocorat is metabolized by cytochrome P450 (CYP)3A to an N-oxide metabolite. Dagrocorat is a reversible inhibitor of several CYPs, such as CYP3A and CYP2D6 ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

REFERENCES

[1]. Ripp SL, et al. In Vitro and In Vivo Investigation of Potential for Complex CYP3A Interaction for PF-00251802 (Dagrocorat), a Novel Dissociated Agonist of the Glucocorticoid Receptor. Clin Pharmacol Drug Dev. 2018 Mar;7(3):244-255.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA